Craven, Kelly E.Gore, JesseKorc, Murray2016-08-032016-08-032016Craven, K. E., Gore, J., & Korc, M. (n.d.). Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. Cancer Letters. http://doi.org/10.1016/j.canlet.2015.11.047https://hdl.handle.net/1805/10560The importance of angiogenesis in pancreatic ductal adenocarcinoma (PDAC) and its therapeutic potential have been explored in both pre-clinical and clinical studies. Human PDACs overexpress a number of angiogenic factors and their cognate high-affinity receptors, and anti-angiogenic agents reduce tumor volume, metastasis, and microvessel density (MVD), and improve survival in subcutaneous and orthotopic pre-clinical models. Nonetheless, clinical trials using anti-angiogenic therapy have been overwhelmingly unsuccessful. This review will focus on these pre-clinical and clinical studies, the potential reasons for failure in the clinical setting, and ways these shortcomings could be addressed in future investigations of angiogenic mechanisms in PDAC.enAttribution-NonCommercial-NoDerivs 3.0 United Statespancreatic cancerAngiogenesisvascular endothelial growth factorArticle